Final week we talked about biotech penny shares with upcoming catalysts. That article obtained a whole lot of consideration and for apparent causes. As I defined, few industries will host corporations that may let you know once they’ve acquired information coming. Biotech is one in all these industries, and it makes for thrilling market situations. You’ve acquired the “purchase the rumor, promote the information” development to navigate.
PennyStocks.com – PennyStocks
Then there’s the market shock the place corporations ship outcomes far surpassing what Wall Road initially thought. One thing to recollect is that there are such a lot of totally different steps concerned in taking a biotech firm from pre-clinical to business levels. Every part presents a milestone alternative.
Biotech shares are thrilling to look at, particularly round these potential milestone occasions. These are all issues to bear in mind, whether or not it’s an trade presentation, new examine information, or one thing else.
The Inventory Market This Week
We’ve acquired a number of issues to bear in mind within the inventory market this week. It’s the ultimate week of September, which suggests an finish to one of the difficult months within the inventory marketplace for 2021. It’s additionally the tip of the third quarter. Over the past 12 months, corporations have reported precise dates and broad intervals.
“By the tip of Q3” is one in all these broad timeframes. So as we speak, we’re going to take a look at 10 top penny stocks presumed to have one thing to take discover of this week. Will these occasions grow to be bullish or bearish catalysts? In case you’re trying to find penny stocks to purchase, I’ll depart that remaining resolution as much as you. On the very least, you’re armed with data heading into the tip of September and the tip of Q3.
Penny Shares To Watch This Week
|1. Zynerba Prescription drugs Inc. (NASDAQ:ZYNE)||September 27, 2021|
|2. Verastem Oncology (NASDAQ:VSTM)||September 27, 2021|
|3. Lineage Cell Therapeutics, Inc. (NYSE:LCTX)||September 27, 2021
September 30, 2021
|4. Rigel Prescription drugs Inc. (NASDAQ:RIGL)||September 28, 2021|
|5. Asensus Surgical Inc. (NYSE:ASXC)||September 28, 2021|
|6. 9 Meters Biopharma Inc. (NASDAQ:NMTR)||September 28, 2021|
|7. Arbutus Biopharma Company (NASDAQ:ABUS)||September 30, 2021|
|8. CTI BioPharma Corp. (NASDAQ:CTIC)||Q3 2021|
|9. ASLAN Prescription drugs Restricted (NASDAQ:ASLN)||Q3 2021|
|10. Precigen Inc. (NASDAQ:PGEN)||October 1, 2021|
Penny Shares To Watch On September 27:
Zynerba Prescription drugs Inc.
Zynerba is likely one of the firm’s we mentioned final week on a list of penny stocks analysts say to buy right now. H.C. Wainwright analyst Oren Livnat reiterated the agency’s Purchase ranking on ZYNE inventory and a worth goal of $9. Apart from that, there are different extra scientific issues to think about when Zynerba. The corporate focuses on transdermal therapies for uncommon and near-rare problems.
It made a number of shows this month on its ZYN002 platform, trademarked as Zygel. This product is a transdermal gel administered to kids with developmental and epileptic encephalopathy. Latest outcomes of ongoing research have demonstrated how Zygel can profit sufferers even throughout longer-term time frames. Sufferers with Autism Spectrum Dysfunction who accomplished a 38-week therapy confirmed “statistically vital enhancements” in comparison with baselines within the examine.
What To Watch With ZYNE Inventory This Week
As you’ll come to seek out, the Cantor World Healthcare Convention shall be a degree of focus for a lot of corporations this week. The convention goes from September 27 – September 30. On September twenty seventh, Zynerba’s CEO Armando Anido begins his presentation at 11:20 AM ET. Preserve this in thoughts if ZYNE is in your record of penny shares this week.
Verastem Oncology Inc.
One other one of many corporations that we’ve incessantly mentioned this month is Verastem. Not solely was it highlighted for bullish analyst sentiment, nevertheless it was additionally spotlighted for a biotech occasion final week. Verastem introduced that examine information in a mixture of its VS-6766 and defactinib demonstrated potential in treating ovarian most cancers. The corporate mentioned that the median progression-free survival throughout all sufferers was 23 months.
Along with these outcomes, Verastem additionally introduced a scientific collaboration settlement with Amgen (NASDAQ:AMGN), evaluating a mixture of VS-6766 with Amgen’s sotorasib, trademarked as LUMAKRAS, in sufferers with non-small cell lung most cancers. This trial is predicted to start by the tip of the 12 months. In order that could possibly be one thing to bear in mind in a while throughout This fall.
What To Watch With VSTM Inventory This Week
Much like Zynerba, VSTM inventory shall be in focus this week as administration presents on the Cantor Convention. September 27 will even be the date to bear in mind right here. The corporate begins its presentation at 4 PM ET.
Lineage Cell Therapeutics
Much like Rigel, the final 12 months was a pivotal one for development in Lineage Cell Therapeutics. Final September, shares of LCTX inventory traded under $1. Heading into this week, they’re firmly buying and selling above $2. Right here’s what’s gone on with Lineage and why this week could possibly be vital for the corporate.
Learn extra: Penny Stock Market Trading Hours You Need To Know
Lineage focuses on allogeneic cell therapies for issues like dry age-related macular degeneration (AMD). Its OpRegen therapy is being studied for this indication in ongoing part trials, having already demonstrated enhancements in examine sufferers. The corporate can also be growing OPC1 for subacute spinal twine accidents and VAC2 to deal with non-small cell lung most cancers.
What To Watch With LCTX Inventory This Week
Lineage is dealing with double-duty this week. The primary date to markdown is September 27. Firm CEO Brian Culley begins presenting at a hearth chat throughout the Cantor Healthcare convention at 4 PM ET. Later this week, up to date interim outcomes from its Section 1/2a examine of OpRegen® shall be featured in a podium presentation on the 54th Annual Scientific Assembly of the Retina Society. This presentation begins on September 30 at 9:52 AM EDT.
Penny Shares To Watch On September 28:
Rigel Prescription drugs Inc.
Regardless of September being a blended month for the corporate’s shares, Rigel has skilled vital development over the past 12 months. This time in 2020, shares of RIGL inventory had been buying and selling barely larger than $2. Heading into this week, the inventory is buying and selling marginally decrease than $4.
The biotech firm develops small molecule medicine for treating hematologic problems, most cancers, and uncommon immune illnesses. The corporate’s first FDA-approved product, TAVALISSE (fostamatinib disodium hexahydrate), is utilized in treating persistent immune thrombocytopenia. Fostamatinib can also be being studied in a number of scientific trials for treating anemia in addition to COVID-19. The latter has helped carry a number of the “hype” issue into the combo this 12 months, because of elevated consideration on COVID shares.
Earlier this month, the outcomes from a Section 2 trial evaluating fostamatinib for hospitalized COVID sufferers had been revealed in Medical Infectious Illnesses. Information confirmed that therapy with fostamatinib was nicely tolerated and related to clinically significant enchancment in outcomes of hospitalized sufferers.
What To Watch With RIGL Inventory This Week
As soon as once more, trade conferences are the main target. This week Rigel’s Raul Rodriguez presents an organization overview at Cantors World Healthcare Convention. Suppose RIGL inventory is in your record, markdown September 28 at 4:40 PM ET. Rodriguez begins his presentation at the moment.
Asensus Surgical Inc.
Shares of ASXC inventory began the 12 months robust. Because the begin of April, the general development has been largely sideways. There was a quick spike in June, however issues have subsided. One of many issues that proceed holding traders’ pursuits is the corporate’s medical system platform. Asensus’ Clever Surgical Unit (ISU) was designed to extend surgeon management and streamline surgical procedure experiences and outcomes. The corporate’s utilization of machine imaginative and prescient and augmented intelligence has introduced a brand new layer of know-how into the working room.
Learn extra: 3 Penny Stocks That You Need to Know About Right Now
Earlier this month, its ISU system obtained FDA 510(ok) clearance to increase machine imaginative and prescient capabilities. That is used with the corporate’s Senhance Surgical System enabling digital laparoscopy.
What To Watch With ASXC Inventory This Week
This week Asensus continues its trade presentation circuit. The third and remaining presentation shall be at, you guessed it, the Cantor Healthcare Convention. Firm CEO Anthony Fernando and CFO Shameze Rampertab start their presentation at 1:20 PM ET on September 28.
9 Meters Biopharma Inc.
The previous couple of weeks for9 Meters Biopharma have been robust. Shares of NMTR inventory moved up from round $1 in mid-August to over $1.30 final week. Serving to enhance sentiment was a mixture of extra strong earnings outcomes and new offers contributing to advancing the corporate’s therapy pipeline.
Particularly, 9 Meters introduced a collaboration with the European Biomedical Analysis Institute of Salerno, Italy (EBRIS). This was to check the corporate’s larazotide to deal with multisystem inflammatory syndrome in kids (MIS-C). Larazotide can also be in Section 3 scientific improvement for adults with celiac illness. EBRIS plans to provoke a Section 2a examine in MIS-C in This fall 2021.
One other aspect of this story bringing curiosity to NMTR inventory is analyst and insider sentiment. In September, Director Mark Sirgo and CFO Edward Sitar purchased a complete of 88,529 between common costs of $1.22 and $1.36. Sirgo accounted for the majority of that, with over 73,000 shares bought at a mean worth of $1.36, bringing his straight managed place to over 1.1 million shares. Analysts at BMO Capital are additionally bullish proper now. The agency has an Outperform ranking on the inventory and a $5 worth goal.
What To Watch This Week With NMTR Inventory
Much like Asensus, 9 Meters is buttoning up a circuit of shows this week. CEO John Temperato presents at Cantor’s Healthcare Convention on September 28, starting at 4:40 PM ET.
Penny Shares To Watch On September 30:
Arbutus Biopharma Company
Shares of Arbutus have been purple scorching over the previous couple of months. Starting in August, ABUS inventory began its climb, benefiting from extra strong gross sales ends in the second quarter along with an upbeat outlook from administration regarding Arbutus’ therapy pipeline.
William Collier, President and Chief Government Officer of Arbutus, defined, “We had a productive second quarter, significantly in advancing our efforts to place AB-729 as a possible cornerstone remedy in future HBV mixture regimens. Our lately introduced proof-of-concept scientific collaborations with Vaccitech plc and Antios Therapeutics, Inc. to judge AB-729 with different brokers displays this goal, as does our deliberate Section 2a scientific trial to judge AB-729 together with Peg-IFNα-2a.”
Loads of the main target has been on Arbutus versus Moderna, imagine it or not. The 2 conflicted over Arbutus’s lipid formulations for nucleic acid supply. Earlier this month, the European Patent Workplace mentioned that its 069 patent associated to lipid formulations was “Ingenious” (legitimate). It was in settlement with the US Patent and Trademark Workplace, which granted a discover of allowance this month. Moderna is transferring ahead with an attraction set for a listening to subsequent month. Nevertheless, if Arbutus is appropriate, it may open the doorways for eligibility to obtain royalties from Moderna’s COVID-19 vaccine gross sales.
What To Watch With ABUS Inventory This Week
The corporate presents on the Cantor World Healthcare Convention that many others on this record of penny shares shall be in attendance this week. CEO William Collier will give the presentation starting at 8:40 AM ET. So if ABUS inventory is in your record proper now, preserve September thirtieth in thoughts.
Penny Shares to Watch At The Finish of Q3:
CTI BioPharma Corp.
CTI Biopharma kicks off the part of this record of penny shares that haven’t given particular dates. Nevertheless, since that is the ultimate week of the third quarter, the countdown has begun for corporations like CTI to ship on their beforehand introduced plans.
The corporate has centered its efforts on advancing its focused therapy platform geared toward blood-related cancers. It targets sufferers with myelofibrosis and extreme COVID-19 in response to the 2020/2021 pandemic. Its present pipeline therapy consists of pacritinib for treating myelofibrosis, which has a New Drug Software underneath assessment by the FDA. There’s a Prescription Drug Person Charge Act date of November thirtieth. In order the fourth quarter begins, that shall be an vital date to bear in mind. Contemplating that the corporate has already began commercialization actions, CTI seems optimistic concerning the FDA’s potential resolution. Nevertheless, because the saying goes, they gained’t know until they know.
What To Watch With CTIC Inventory This Week
This week could possibly be all about COVID 19 for CTI Biopharma. In its second-quarter monetary outcomes and enterprise replace, administration defined that they anticipate to ship interim evaluation from a Section 3 PRE-VENT trial in hospitalized sufferers with extreme COVID-19 this quarter.
ASLAN Prescription drugs
One other one of many “Q3 penny shares to look at” is ASLAN Prescription drugs. The corporate focuses on remedies for immune illnesses. It’s at present evaluating a number of therapy candidates. Its ASLAN004 targets atopic dermatitis, and its ASLAN003 focuses on autoimmune illness.
What To Watch With ASLN Inventory This Week
In June, the corporate accomplished the recruitment of 27 sufferers into the enlargement cohort of the double-blind placebo-controlled a number of ascending dose examine. Topline information is predicted on the finish of this quarter, based on the corporate’s August sixth replace. One thing to take into accounts is that earlier this 12 months, information from a single ascending dose examine demonstrated that ASLAN004 has a positive tolerability profile and potential as a special therapy methodology for atopic dermatitis. With the a number of ascending dose examine yield an analogous response?
Penny Shares To Watch On October 1:
On the upper finish of the penny inventory vary, Precigen shall be on the record of penny shares to look at this week. However you’ll have to attend just a few days for its potential catalyst date. One thing to know concerning the firm is that it’s labored diligently on advancing its gene and cell therapies with this 12 months as an vital one for the corporate.
Administration elaborated on this in its newest quarterly enterprise replace. Helen Sabzevari, Ph.D., President, and CEO of Precigen, mentioned, “We see 2021 as a pivotal 12 months for the UltraCAR-T, ActoBiotics, and AdenoVerse platforms with vital new scientific information on our most superior therapeutic candidates from these core therapeutic platforms.”
What To Watch With PGEN Inventory This Week
ActoBiotics is also referred to as AG019 ActoBiotics, would be the focus this week. Extra information from its AG019 Section 1b/2a scientific trial shall be offered on October 1 at midday CET as an oral presentation on the European Affiliation for the Examine of Diabetes Assembly. The summary entitled, “AG019 ActoBiotics as monotherapy or in affiliation with teplizumab in recent-onset sort 1 diabetes was protected and demonstrated encouraging metabolic and immunological results” shall be offered by Chantal Mathieu, MD, Ph.D., Professor of Medication on the Katholieke Universiteit Leuven, Belgium. As well as, a scientific trial assessing the efficacy of extended therapy of oral AG019 can also be deliberate.
One thing to notice is that constructive topline information from the AG019 Section 1b/2a scientific trial had been reported earlier this 12 months on the Federation of Medical Immunology Societies Assembly. The first endpoints of security and tolerability for the Section 1b AG019 monotherapy and the Section 2a AG019 mixture remedy had been met. No critical adversarial occasions had been reported both.
Penny Shares To Watch This Week
There are various biotech penny shares to look at this week, together with those talked about on this article. Needless to say simply because the corporate has beforehand introduced a date, that doesn’t imply data launched shall be constructive (or adverse, for that matter). Nevertheless, what it does imply is that there could possibly be new data to think about. With that may come loads of volatility and, if favorable, alternatives to capitalize. Will that be the case this week?